In past months, a couple of very interesting studies suggested that patients with ALK-driven cancer might be more likely than others to be super-responders to Alimta (pemetrexed). New research now suggests that might actually not have been a correlation directly with ALK+ status, and the incremental benefit might be a little less than previously thought.
== ALK+ Alimta-Sensitivity Hypothesis ==
The ALK+ super-responder hypothesis for Alimta was originated by Dr. Ross Camidge, the best "superdoc" in the Western states for ALK. Here's where you can read the abstract of that research:
"ALK Gene Rearrangements in NSCLC Are Associated with Prolonged Progression-Free Survival on Pemetrexed"
And a few months later, research from Korea seemed to confirm that pattern:
"ALK Translocation: A Predictive Biomarker of Pemetrexed in Patients with NSCLC"
Now we have this:
== The New Research ==
"Pemetrexed-based Chemotherapy in Patients with Advanced, ALK-positive NSCLC"
by Alice Shaw, MD, PhD and an international team with patient data from cancer centers in Boston, New York City, East Melbourne Australia, and Torino Italy.
The abstract concludes with:
- PFS on pemetrexed or non-platinum/pemetrexed combinations was similar in ALK-positive and ALK-negative patients.
- PFS on first-line platinum/pemetrexed may be prolonged in never/light-smoking patients regardless of ALK status.
(see below continuation in my reply to myself, due to the #characters-limit here.)